(00:21) Asit Sharma and Dylan Lewis discuss:
- How the airline industry’s focus on capacity and being able to supply more flights means fares are low, even in the face of record demand.
- Eli Lilly’s $3.2B acquisition of Morphic, why it’s interested in the inflammatory bowel disease markets, and a few risks to keep in mind for the high-flying provider of weight-loss drugs.
(14:39) Fool analyst Kirsten Guerra talks with Mary Long about her investing journey, and a career pivot that took her from rocks to stocks.
Companies discussed: DAL, UAL, AAL, JBLU, LUV, LLY, MORF
Host: Dylan Lewis
Guests: Asit Sharma, Kirsten Guerra, Mary Long
Producer: Ricky Mulvey
Engineers: Dan Boyd
Learn more about your ad choices. Visit megaphone.fm/adchoices
Create your
podcast in
minutes
It is Free